Antibody therapy for breast cancer

Anticancer Research

Volumn 25, Issue 3 A, 2005, Pages 1483-1489

  Willems, Amina ^a   Gauger, Katja ^a   Henrichs, Cordula ^a   Harbeck, Nadia ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

2C4; Adjuvant therapy; HER2 neu; Herceptin ; Metastatic breast cancer; Pertuzumab; Review; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIBODY; CAPECITABINE; CARBOPLATIN; DOCETAXEL; NAVELBINE; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB;

ABDOMINAL PAIN; ANEMIA; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; FEVER; FLU LIKE SYNDROME; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TOXICITY; MONOTHERAPY; ONCOGENE NEU; PAIN; PATIENT SELECTION; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE;

EID: 21244467171     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Yamauchi H, Stearns V and Hayes DF: When is a tumor marker ready for prime time? A case study of c-erbB as a predictive factor in breast cancer. JCO 19(8): 2334-2356, 2001.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177-182, 1987.
3. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ and Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20(3): 719-726, 2002.
4. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G and Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic disease. JCO 17: 2639-2648, 1999
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEJM 344: 783-792, 2001.
6. Mass R, Press M, Anderson S and Slamon D: Improved survival benefit from Herceptin (trastuzumab) and chemotherapy in patients selected by fluorescence in situ hybridisation. Breast Cancer Res Treat 69: 213 (Abstract 18), 2001.
7. Paik S, Bryant J, Tan-Chiu E, Romond E, Killer W, Park K, Brown A, Yothers G, Anderson S, Smith R, Wickerham DL and Wolmark N: Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. JNCI 94(11): 852-854, 2002.
8. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN and Perez EA: Concordance between local and central laboratory HER-2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94: 855-857, 2002.
9. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL and Hortobagyi GN: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20(7): 1800-1808, 2002.
10. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R and Winer EP: Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21(15): 2889-2895, 2003.
11. Extra JM, Cognetti F, Chan S, Maraninchi D, Snyder R, Lluch A, Tubiana-Hulin M, Grimes D, Mayne K and Marty M: Randomized phase II trial (M77001) of trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastatic breast cancer. Eur J Cancer 7(5): S202, 2003.
12. Pietras RJ, Pegram MD, Finn RS, Maneval DA and Slamon DJ: Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17(17): 2235-2249, 1998.
13. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F and Slamon D: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18(13): 2241-2251, 1999.
14. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA and Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16(8): 2659-2671, 1998.
15. Rowland KM, Suman VJ, Ingle JN, Loprinzi CL, Flynn PJ, Krook JE, Salim M, Mailliard JA, Kardinal CG and Perez EA: NCCTG 98-32-52: randomized phase II trial of weekly versus every 3-week administration of paclitaxel, carboplatin and trastuzumab in women with HER2 positive metastatic breast cancer (MBC). ASCO Proc 22: 31, 2003.
16. Pegram MD, Lopez A, Konecny G and Slamon DJ: Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 27(6 suppl 11): 21-25, discussion 92-100, 2000.
17. Kubo M, Morisaki T, Kuroki H, Tasaki A, Yamanaka N, Matsumoto K, Nakamura K, Onishi H, Buba E and Katano M: Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer. Anticancer Res 23(6A): 4443-4449, 2003.
18. Christodoulou C, Klouvas G, Pateli M, Mellou S, Sgouros J and Skarlos DV: Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast-cancer. Anticancer Res 23(1B): 737-744, 2003.
19. Rossi A, Colantuoni G, Cantore N, Panico L, De Chiara G, Ferbo U and Gridelli C: Complete response of severe symptomatic bone marrow metastases from heavily pretreated breast cancer with a 3-weekly trastuzumbab schedule. A clinical case Anticancer Res 24(1): 317-319, 2004.
20. Geyer CE Jr., Bryant J, Romond E, Tan-Chiu E, Ewer M, Keefe D, Shannon R, Yothers G, Brown A, Fehrenbacher L, Vogel V, Seay TE, Flynn PJ and Wolmark N: Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of Adriamycin and cyclophosphamide (AC) followed by Taxol to that of AC followed by Taxol plus Herceptin in patients (Pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC). Breast Cancer Res Treat 82(suppl 1):S2. Abstract 23, 2003.
21. Ross JS and Fletcher JA: The HER2/neu oncogene in breast cancer: prognostic factor, predictive factor and target for therapy. Oncologist, 3(4): 237-252, 1998.
22. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI and Sliwkowski MX: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2: 127-137, 2002.
23. Agus DB, Gordon M, Taylor C, Natale RB, Karlan B, Mendelson D, Kelsey S and Fyfe G: Clinical activity in a phase I trial of HER-2-targeted rhuMAb 2C4 (pertuzumab) in patients with advanced solid malignancies (AST). ASCO Proc 22: 771, 2003.
24. Peto R, Boreham J, Clarke M, Davies C and Beral V: UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355(9217): 1822, 2000.